CoChat

PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases

Open access

The DOI matches its Crossref record; 83 of the 84 references it cites were found in a registry or an index.

Abstract

Cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), result from an impairment of bile flow that leads to the hepatic retention of bile acids, causing liver injury. Until recently, the only approved treatments for PBC were ursodeoxycholic acid (UDCA) and obeticholic acid (OCA). While these therapies slow the progression of PBC in the early stage of the disease, approximately 40% of patients respond incompletely to UDCA, and advanced cases do not respond. UDCA does not improve survival in patients with PSC, and patients often have dose-limiting pruritus reactions to OCA. Left untreated, these diseases can progress to fibrosis and cirrhosis, resulting in liver failure and the need for transplantation. These shortcomings emphasize the urgent need for alternative treatment strategies. Recently, nuclear hormone receptors have been explored as pharmacological targets for adjunct therapy because they regulate enzymes involved in bile acid metabolism and detoxification. In particular, the peroxisome proliferator-activated receptor (PPAR) has emerged as a therapeutic target for patients with PBC or PSC who experience an incomplete response to UDCA. PPARα is predominantly expressed in the liver, and it plays an essential role in the regulation of cytochrome P450 (CYP) and uridine 5’-diphospho-glucuronosyltransferase (UGT) enzymes, both of which are critical enzyme families involved in the regulation of bile acid metabolism and glucuronidation, respectively. Importantly, PPARα agonists, e.g., fenofibrate, have shown therapeutic benefits in reducing elevated markers of cholestasis in patients with PBC and PSC, and elafibranor, the first PPAR (dual α, β/δ) agonist, has been FDA-approved for the second-line treatment of PBC. Additionally, newer PPAR agonists that target various PPAR isoforms (β/δ, γ) are under development as an adjunct therapy for PBC or PSC, although their impact on glucuronidation pathways are less characterized. This review will focus on PPAR-mediated bile acid glucuronidation as a therapeutic pathway to improve outcomes for patients with PBC and PSC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cells13151296

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Two major bile acid biosynthetic pathways are shown. In the classic pathway, cytochrome P450 (CYP)7A1 converts cholesterol to 7α-hydroxycholesterol, which is converted to 7α-hydroxy-4-cholesten-3-one (C4) by 3β-hydroxysteroid dehydrogenase (HSD3B7). C4 is converted to cholic acid (CA) by CYP8B1 or to chenodeoxycholic acid (CDCA). In the alternative pathway, CYP27A1 or CYP3A4 converts cholesterol to 25(R)-26-hydroxycholesterol, followed by hydroxylation by CYP7B1 for the eventual synthesis of CA and CDCA. CA is converted to deoxycholic acid (DCA), and CDCA can be converted to lithocholic acid (LCA) or hyocholic acid (HCA). LCA can be hydroxylated to form hyodeoxycholic acid (HDCA). Uridine 5’-diphospho-glucuronosyltransferase (UGT) enzymes catalyze the glucuronidation of these bile acids to form -3, -6, or -24-glucuronides (-G). Bile acid glucuronides (BA-Gs) are transported out of the liver and into the bile canalicular space via the multidrug resistance-associated protein (MRP)-2 and pass through the common bile duct, gallbladder, and intestines, where they can be recycled back to the liver via enterohepatic recirculation. Alternatively, BA-Gs can be transported out of the liver and into systemic circulation via MRP3 and MRP4 for eventual renal excretion into urine. Image created with BioRender.com.
Figure 1 Two major bile acid biosynthetic pathways are shown. In the classic pathway, cytochrome P450 (CYP)7A1 converts cholesterol to 7α-hydroxycholesterol, which is converted to 7α-hydroxy-4-cholesten-3-one (C4) by 3β-hydroxysteroid dehydrogenase (HSD3B7). C4 is converted to cholic acid (CA) by CYP8B1 or to chenodeoxycholic acid (CDCA). In the alternative pathway, CYP27A1 or CYP3A4 converts cholesterol to 25(R)-26-hydroxycholesterol, followed by hydroxylation by CYP7B1 for the eventual synthesis of CA and CDCA. CA is converted to deoxycholic acid (DCA), and CDCA can be converted to lithocholic acid (LCA) or hyocholic acid (HCA). LCA can be hydroxylated to form hyodeoxycholic acid (HDCA). Uridine 5’-diphospho-glucuronosyltransferase (UGT) enzymes catalyze the glucuronidation of these bile acids to form -3, -6, or -24-glucuronides (-G). Bile acid glucuronides (BA-Gs) are transported out of the liver and into the bile canalicular space via the multidrug resistance-associated protein (MRP)-2 and pass through the common bile duct, gallbladder, and intestines, where they can be recycled back to the liver via enterohepatic recirculation. Alternatively, BA-Gs can be transported out of the liver and into systemic circulation via MRP3 and MRP4 for eventual renal excretion into urine. Image created with BioRender.com.CC BY · PubMed Central
Figure 2 Combination treatment with UDCA and fenofibrate alters the concentration and composition of -3/6 bile acid glucuronides during cholestatic liver diseases. Serum was collected from patients treated with either UDCA monotherapy (13–15 mg/kg/day)—“mono”—or combination treatment with UDCA and fenofibrate (145–160 mg/day)—“combo”. Serum bile acid glucuronide concentrations were measured using LC-MS/MS methodology. Data represent the total concentration of -3 and -6 bile acid glucuronides within each patient cohort [18]. PBC (n = 16 “mono”, n = 16 “combo”) and PSC (n = 11 “mono”, n = 12 “combo”). UDCA: ursodeoxycholic acid; PBC: primary biliary cholangitis; PSC: primary sclerosing cholangitis; LCA: lithocholic acid; DCA: deoxycholic acid; HCA: hyocholic acid; HDCA: hyodeoxycholic acid; CDCA: chenodeoxycholic acid.
Figure 2 Combination treatment with UDCA and fenofibrate alters the concentration and composition of -3/6 bile acid glucuronides during cholestatic liver diseases. Serum was collected from patients treated with either UDCA monotherapy (13–15 mg/kg/day)—“mono”—or combination treatment with UDCA and fenofibrate (145–160 mg/day)—“combo”. Serum bile acid glucuronide concentrations were measured using LC-MS/MS methodology. Data represent the total concentration of -3 and -6 bile acid glucuronides within each patient cohort [18]. PBC (n = 16 “mono”, n = 16 “combo”) and PSC (n = 11 “mono”, n = 12 “combo”). UDCA: ursodeoxycholic acid; PBC: primary biliary cholangitis; PSC: primary sclerosing cholangitis; LCA: lithocholic acid; DCA: deoxycholic acid; HCA: hyocholic acid; HDCA: hyodeoxycholic acid; CDCA: chenodeoxycholic acid.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 83 references

Cited by

See all 40

Metadata

Authors
Gallucci, G. M., Hayes, C. M., Boyer, J. L., Barbier, O., Assis, D. N., & Ghonem, N. S.
Affiliations
  • University of Rhode Island (US)
  • Yale University (US)
  • Université Laval (CA)
Corresponding author
Ghonem, Nisanne S.
Venue
Cells
Publisher
MDPI AG
Published
2024-08-01
Volume
13
Issue
15
Pages
1296
ISSN
2073-4409 (ISSN-L)
OpenAlex
W4401218243
Cited by
40
References
84
Citations by year
2026: 17 · 2025: 22 · 2024: 1
FWCI
2.88
Type
journal article
Language
en
Open access
Locations
  • Cells (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
Keywords
peroxisome proliferator-activated receptors, cholestatic liver disease, primary biliary cirrhosis, primary sclerosing cholangitis, PPARα agonist, fenofibrate, elafibranor, ursodeoxycholic acid, obeticholic acid, UGT enzymes, CYP enzymes, bile acid metabolism, nuclear receptors, adjunctive therapy
MeSH terms
Animals, Bile Acids and Salts, Cholestasis, Humans, Liver Cirrhosis, Biliary, Cholangitis, Sclerosing, Peroxisome Proliferator-Activated Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases. https://app.cochat.ai/papers/10.3390/cells13151296
The paper
Gallucci, G. M., Hayes, C. M., Boyer, J. L., Barbier, O., Assis, D. N., & Ghonem, N. S. (2024). PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases. Cells. https://doi.org/10.3390/cells13151296

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.